Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)

Completed

Conditions studied: Primary Aldosteronism

In brief

The mission of this project is to increase the detection of Primary Aldosteronism (PA), the most common cause of secondary hypertension, which can either be cured surgically or treated with targeted medications.

Key facts

Study ID

NCT05757076

Run by

The Cleveland Clinic

People needed

53

Starts

2023-05-02

Expected to finish

2025-12-29

Last updated by the study team

2026-02-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Consent to participate in the study
• Participants limited to subjects in the CCF
• Age between and inclusive of 18 and 65 years of age
• No gender exclusion
• Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension
• Patients on a single anti-hypertensive medication for at least six months with the diagnosis of hypertension

You may not qualify if…

• Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)
• Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism
• Those with a diagnosis of secondary hyperaldosteronism
• Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.
• Pregnancy status (verbal)

Where it is running

• The Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.